Tuin 2019.

Trial name or title	Comparative study of the efficacy of induction therapy with cyclophosphamide or mycophenolate mofetil for non‐life‐threatening relapses of PR3‐ or MPO‐ANCA associated vasculitis
Methods	Open RCT, safety and efficacy study
Participants	Males and females ≥ 18 years
Interventions	When relapses occur, patients will be randomised for either the standard therapy with CPA or for MMF
Outcomes	Primary outcome measures Remission induction rate Disease‐free survival after 2 and 4 years Secondary outcome measures Time to remission Cumulative organ damage Side‐effects ANCA titres over time
Starting date	December 2004
Contact information	Patricia M. Stassen, M.D. +31503611295 p.m.stassen@int.umcg.nl
Notes

ANCA ‐ anti‐neutrophil cytoplasmic antibody; AZA ‐ azathioprine; BVAS ‐ Birmingham Vasculitis Activity Score; CPA ‐ cyclophosphamide; eGFR ‐ estimated glomerular filtration rate; IVIg ‐ intravenous immunoglobulin; MMF ‐ mycophenolate mofetil; MPO ‐ myeloperoxidase; MTX ‐ methotrexate; PR3 ‐ proteinase‐3; RCT ‐ randomised controlled trial; rituximab ‐ RTX; WG ‐ Wegener's granulomatosis